1.035
price up icon5.49%   0.0539
pre-market  Pre-mercato:  1.08   0.045   +4.35%
loading
Precedente Chiudi:
$0.9811
Aprire:
$1.07
Volume 24 ore:
6.92M
Relative Volume:
1.56
Capitalizzazione di mercato:
$330.00M
Reddito:
-
Utile/perdita netta:
$-63.08M
Rapporto P/E:
-3.8333
EPS:
-0.27
Flusso di cassa netto:
$-72.53M
1 W Prestazione:
-5.05%
1M Prestazione:
+11.19%
6M Prestazione:
+44.11%
1 anno Prestazione:
-17.86%
Intervallo 1D:
Value
$1.01
$1.15
Intervallo di 1 settimana:
Value
$0.954
$1.15
Portata 52W:
Value
$0.515
$1.979

Ocugen Inc Stock (OCGN) Company Profile

Name
Nome
Ocugen Inc
Name
Telefono
484-328-4701
Name
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Name
Dipendente
95
Name
Cinguettio
@Ocugen
Name
Prossima data di guadagno
2025-05-02
Name
Ultimi documenti SEC
Name
OCGN's Discussions on Twitter

Confronta OCGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
OCGN
Ocugen Inc
1.035 330.00M 0 -63.08M -72.53M -0.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Ocugen Inc Stock (OCGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-10-15 Iniziato Maxim Group Buy
2023-03-01 Aggiornamento Chardan Capital Markets Neutral → Buy
2022-08-23 Iniziato Mizuho Buy
2022-06-15 Ripresa ROTH Capital Buy
2022-06-02 Iniziato Cantor Fitzgerald Overweight
2021-07-26 Iniziato Noble Capital Markets Outperform
2021-06-11 Downgrade ROTH Capital Buy → Neutral
2021-05-07 Downgrade Cantor Fitzgerald Overweight → Neutral
2021-02-09 Downgrade Chardan Capital Markets Buy → Neutral
2021-02-04 Aggiornamento H.C. Wainwright Neutral → Buy
Mostra tutto

Ocugen Inc Borsa (OCGN) Ultime notizie

pulisher
Jun 18, 2025

Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 17, 2025

FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Ocugen to Release New Investor Presentation - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

Ocugen gets FDA clearance to begin mid-stage study of OCU410ST - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA - Ophthalmology Times

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

FDA clears Ocugen’s phase 2/3 trial for Stargardt disease therapy - Investing.com

Jun 16, 2025
pulisher
Jun 13, 2025

Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention - MSN

Jun 13, 2025
pulisher
Jun 11, 2025

Ocugen To Present at BIO International Convention 2025 | OCGN St - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen To Present at BIO International Convention 2025 - Ocugen

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen To Present at BIO International Convention 2025 | OCGN Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN

Jun 10, 2025
pulisher
Jun 09, 2025

Ocugen Secures Licensing Agreement for OCU400 in Korea - MSN

Jun 09, 2025
pulisher
Jun 08, 2025

Ocugen signs license deal with Korean company for gene therapy - MSN

Jun 08, 2025
pulisher
Jun 08, 2025

Ocugen, Inc. (NASDAQ:OCGN) Position Boosted by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Ameriprise Financial Inc. Invests $30,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

Ocugen Signs License Agreement for OCU400 in Korea - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock rises on Korean licensing deal for gene therapy By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha

Jun 05, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Acquires Shares of 36,859 Ocugen, Inc. (NASDAQ:OCGN) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400 - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the Lic - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene ... - Bluefield Daily Telegraph

Jun 05, 2025
pulisher
Jun 05, 2025

OCGNOcugen Provides Business Update with First Quarter 2025 Financial Results - Revista ADVFN

Jun 05, 2025
pulisher
Jun 04, 2025

Ocugen, Inc. (NASDAQ:OCGN) Stock Position Raised by ProShare Advisors LLC - Defense World

Jun 04, 2025
pulisher
Jun 02, 2025

Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy - VISTA.Today

Jun 02, 2025
pulisher
Jun 01, 2025

Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN

Jun 01, 2025
pulisher
May 31, 2025

Ocugen Receives Rare Pediatric Disease Designation for OCU410ST - MSN

May 31, 2025
pulisher
May 29, 2025

FDA awards Ocugen drug with Rare Pediatric Disease Designation - Pennsylvania Business Report -

May 29, 2025
pulisher
May 28, 2025

Ocugen’s Gene Therapy OCU410ST Nets Rare Pediatric Disease Designation for ABCA4-Associated Retinopathies - CGTLive®

May 28, 2025
pulisher
May 28, 2025

Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - MSN

May 28, 2025

Ocugen Inc Azioni (OCGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Ocugen Inc Azioni (OCGN) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Fernandes Prabhavathi
Director
Nov 26 '24
Buy
0.91
10,000
9,095
10,000
Castillo Kirsten
Director
Nov 22 '24
Buy
0.91
25,000
22,848
75,000
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
Capitalizzazione:     |  Volume (24 ore):